A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor

Conclusion: Biosimilar recombinant activated FVII is found to be as effective as Novoseven in the treatment of acute joint bleeding in patients with hemophilia with inhibitors. Its usage will decrease the gaps in hemophilia.

http://cat.sagepub.com/cgi/content/abstract/22/2/184?rss=1

Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2016 Category: Hematology Authors: Faranoush, M., Abolghasemi, H., Mahboudi, F., Toogeh, G., Karimi, M., Eshghi, P., Managhchi, M., Hoorfar, H., Dehdezi, B. K., Mehrvar, A., khoeiny, B., Vaziri, B., Kamyar, K., Heshmat, R., Baghaeipour, M. R., Mirbehbahani, N. B., Fayazfar, R., Ahmadinejad Tags: Original Articles Source Type: research